Biomedicines, Volume 12, Issue 9
2024 September - 230 articles
Cover Story: Duchenne muscular dystrophy (DMD) is an X-linked, progressive, and lethal muscle-degenerating disease caused by a lack of dystrophin. Currently, there is no cure for DMD, but DT-DEC01 represents a novel breakthrough therapy based on the PEG-mediated fusion of myoblasts from a healthy donor (MBN) and a patient with DMD (MBDMD). Following intraosseous administration, DT-DEC01 expresses critical muscle proteins, dystrophin (DYS), myosin heavy chain (MyHC), and desmin (DES), all essential for muscle repair. DT-DEC01 transfers healthy and chimeric mitochondria to the cells of patients with DMD, enhancing muscle regeneration and function. Donor chimerism confirmed by STR loci analysis combined with myogenic differentiation and myotube formation introduce DT DEC01 as a new, viable therapeutic approach for patients with DMD. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.